AI Article Synopsis
- Early diagnosis and effective management of cancer is challenging with traditional tissue biopsies, leading to a search for non-invasive alternatives.
- Blood-based liquid biopsies, particularly microRNAs (miRNAs), offer promising cancer biomarkers for early detection and treatment monitoring.
- The text discusses the history, ongoing controversies, and future hurdles of integrating miRNAs into clinical practice for cancer treatment.
Article Abstract
The effective and efficient management of cancer patients relies upon early diagnosis and/or the monitoring of treatment, something that is often difficult to achieve using standard tissue biopsy techniques. Biological fluids such as blood hold great possibilities as a source of non-invasive cancer biomarkers that can act as surrogate markers to biopsy-based sampling. The non-invasive nature of these "liquid biopsies" ultimately means that cancer detection may be earlier and that the ability to monitor disease progression and/or treatment response represents a paradigm shift in the treatment of cancer patients. Below, we review one of the most promising classes of circulating cancer biomarkers: microRNAs (miRNAs). In particular, we will consider their history, the controversy surrounding their origin and biology, and, most importantly, the hurdles that remain to be overcome if they are really to become part of future clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881453 | PMC |
| http://dx.doi.org/10.3390/ijms17050627 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!